Evidence-Based Complementary and Alternative Medicine has retracted the article titled "Psorinum erapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study" [ ] due to concerns about the ethics, authorship, quality of reporting, and misleading conclusions.
Aradeep and Ashim Chatterjee own and manage the Critical Cancer Management Research Centre and Clinic (CCMRCC), the private clinic to which they are a liated.
e methods state " e study protocol was approved by the Institutional Review Board (IRB approval Number: -) of the CCMRCC" in , but a review of Psorinum therapy said CCMRCC was founded in [ ]. e study states " e participants received the drug Psorinum along with allopathic and homeopathic supportive treatments without trying conventional or any other investigational cancer treatments"; withholding conventional cancer treatment raises ethical concerns.
We asked the authors and their institutions for documentation of the ethics approval, the study protocol, and a blank copy of the informed consent form. However, the corresponding author, Aradeep Chatterjee, was reported to have been arrested in June for allegedly practising medicine without the correct quali cations and his co-author and father Ashim Chatterjee was reported to have been arrested in August; the Chatterjees and their legal representative did not respond to our queries. e co-authors Syamsundar Mandal, Sudin Bhattacharya, and Bishnu Mukhopadhyay said they did not agree to be authors of the article and were not aware of its submission; co-author Jaydip Biswas did not respond.
A member of the editorial board noted that although the discussion stated that " e limitation of this study is that it did not have any placebo or treatment control arm; therefore, it cannot be concluded that Psorinum erapy is e ective in improving the survival and the quality of life of the participants due to the academic rigours of the scienti c clinical trials", the abstract was misleading because it implied Psorinum therapy is e ective in cancer treatment. e study design was described as a "prospective observational clinical trial", but it cannot have been both observational and a clinical trial.
